These data are in agreement with previous in vitro studies that showed that pirfenidone can downregulate proinflammatory cytokines, such as TNF-α, IFN-γ, and interleukin (IL)-6, and improve survival in a murine model of lipopolysaccharide-induced acute lung injury. This evidence concerns the gene TNF and injury.